Profound sedation, respiratory depression, coma, and death may result from the concomitant use of Buprenex with benzodiazepines or other CNS depressants (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol).
The MOU is developed through a process of negotiation and mutual assent, finalized through acceptance of the MOU instrument, and approved by the appropriate agency representatives who signify such approval by signing the MOU.
MOUs must contain the following critical language, issued by USAIDâs General Counselâs office: This language is included in the MOU template. If the template is not used, please include this language in the final MOU. HOW DETAILED DOES THE MOU HAVE TO BE? MOUs can be very short and general in scope or longer and more detailed. In some cases, a more detailed MOU can help provide a better roadmap for the partnership going forward.